Amy E. Tapper - 01 Feb 2022 Form 4 Insider Report for Imago BioSciences, Inc. (IMGO)

Role
Senior Vice President, Non-Clinical and CMC
Signature
/s/ Hugh Rienhoff, as Attorney-in-fact for Amy Tapper
Issuer symbol
IMGO
Transactions as of
01 Feb 2022
Transactions value $
-$114,762
Form type
4
Date filed
03 Feb 2022, 15:13
Previous filing
14 Jan 2022
Next filing
11 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMGO Common Stock Options Exercise $13.7K +6.5K +5.46% $2.10* 126K 01 Feb 2022 Direct F1
transaction IMGO Common Stock Sale -$113K -5.75K -4.58% $19.69 120K 01 Feb 2022 Direct F1, F2
transaction IMGO Common Stock Sale -$15.2K -750 -0.63% $20.26 119K 01 Feb 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGO Stock Option (Right to Buy) Options Exercise $0 -6.5K -10.92% $0.00 53K 01 Feb 2022 Common Stock 6.5K $2.10 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The transaction was executed in multiple trades in prices ranging from $19.21 to $20.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 The transaction was executed in multiple trades in prices ranging from $20.22 to $20.30, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 The Option vests with respect to 25% of the shares subject thereto on July 7, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Senior Vice President, Non-Clinical and CMC